4,900 trials registered in 2024, 13% of global trial site usage, and a domestic biotech sector shifting from me-too drugs to globally first-in-class innovations; China is reshaping the clinical research world.
China is the world's second-most populous country, with a population of roughly 1.41 billion people and the second-largest economy (GDP ~$18 trillion), with a healthcare system that spans over 35,000 hospitals and covers more than 95% of the population through public insurance schemes. In just over a decade, China has transformed itself from a peripheral participant in global clinical research into the world's second-most-used trial site, accounting for 13% of global trial site usage; closing rapidly on the US at 16%.
Clinical trials in China are regulated by the National Medical Products Administration (NMPA) and its technical arm, the Center for Drug Evaluation (CDE). A series of landmark regulatory reforms beginning in 2015; including ICH membership in 2017, the introduction of priority review pathways, and the streamlining of IND applications to a 60-day no-objection process; transformed China's pharmaceutical regulatory environment and triggered a wave of both domestic innovation and international investment. In 2024, the NMPA approved a record 46 Class 1 innovative drugs, 39 of which were domestically developed.
China's 1.4 billion people represent extraordinary scale; and important specificity. The population is predominantly Han Chinese (~92%), with 55 officially recognized ethnic minority groups comprising the remainder. This means China offers unparalleled patient volume for trials but limited ethnic diversity compared to Brazil or the US. However, for trials targeting conditions with high prevalence in East Asian populations; gastric cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and certain genetic variants; China's population is uniquely valuable.
The country's disease burden is substantial and rapidly shifting: cancer, cardiovascular disease, and diabetes are the three largest drivers of trial activity. China has the world's highest absolute burden of stomach cancer, liver cancer, and lung cancer; making it an essential site for oncology research in these tumor types. Life expectancy has risen to 78 years, and an aging population is increasing demand for research in neurodegenerative diseases, metabolic disorders, and age-related conditions.
Innovation shift: In 2024, 68.3% of innovative drug trials in China were for "Category 1" new drugs; molecules not yet approved anywhere in the world. This marks a historic shift from China's historical reputation as a fast-follower market to a genuine global source of first-in-class innovation, particularly in ADCs, bispecific antibodies, and cell therapies.
China's appeal rests on three pillars: scale, speed, and a rapidly maturing scientific ecosystem. Trial volume rose from roughly one-third of US levels in 2019 to approximately 0.8x by 2024; a trajectory that points to parity within this decade. The NMPA's 60-day IND no-objection process, ICH-GCP alignment, and priority review pathways have made China markedly more sponsor-friendly. Cell and gene therapy trials grew 42% in 2024 alone, and 115 CGT trials were registered; reflecting China's emerging global leadership in this space.
60-day IND no-objection window; NMPA priority review for breakthrough therapies; 4,900 trials registered in 2024 (+13.9% vs 2023). Simultaneous NMPA and ethics committee review now permitted for efficiency.
Significantly lower per-patient costs than the US or Western Europe; competitive investigator fees; large patient volumes at leading sites reduce per-patient recruitment costs; government subsidies for innovative drug R&D.
1.4 billion people with high disease burden in oncology, cardiovascular, and metabolic areas; large treatment-naïve pools; unique East Asian genetic profile valuable for pharmacogenomics; 95%+ public insurance coverage.
35,000+ hospitals; world-class academic medical centers in Beijing, Shanghai, and Guangzhou; rapidly growing biotech sector (BeiGene, Zymeworks, Zai Lab); Greater Bay Area (Guangzhou-Shenzhen-Hong Kong) life sciences cluster.
Oncology leads overwhelmingly; 44% of all Chinese trials, including 24.7% of small molecule trials and 43.1% of biologics trials. China is the world's leading site for gastric, liver, and lung cancer research given its uniquely high disease burden in these areas. Cell and gene therapy is the fastest-growing segment (+42% in 2024), with 115 registered CGT trials. Cardiovascular, respiratory, and neurological disorders round out the top five. Rare disease trials; 121 registered in 2024; are a growing priority supported by dedicated NMPA pathways including priority review and conditional approval.
China's research activity is concentrated in Beijing, Shanghai, and Guangzhou; the three major academic medical center cities. Leading hospitals affiliated with Peking University, Fudan University, and Sun Yat-sen University anchor the national ecosystem, with Shanghai's rapidly growing biotech cluster (Pudong, Zhangjiang) adding private-sector depth.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Peking Union Medical College Hospital (PUMCH) | Beijing | China's most prestigious academic hospital; affiliated with Chinese Academy of Medical Sciences; broad Phase I; IV portfolio; strong in oncology, rare diseases, and cardiovascular trials; highest research output of any Chinese hospital. |
| 02 | Cancer Hospital; Chinese Academy of Medical Sciences | Beijing | China's national cancer center; leading oncology research institution; Phase I; III across all major tumor types; partner of NCI, IARC, and major multinational sponsors; lung, gastric, esophageal, and cervical cancer specialty. |
| 03 | Fudan University Shanghai Cancer Center (FUSCC) | Shanghai | China's largest cancer specialty hospital; 4,000+ beds; Phase I; IV oncology; breast, GI, thoracic, and hematologic malignancy focus; advanced translational research; international sponsor partnerships with Roche, AZ, BMS. |
| 04 | Ruijin Hospital; Shanghai Jiao Tong University School of Medicine | Shanghai | Premier Shanghai general academic hospital; hematology pioneer (APL treatment developed here); oncology, hematology, endocrinology trials; Phase I unit; major multinational CRO partner site. |
| 05 | Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou | South China's leading cancer center; global authority on nasopharyngeal carcinoma; Phase I; III across all major tumor types; strong international research partnerships; access to Southern Chinese and Southeast Asian population genetics. |
| 06 | Zhongshan Hospital; Fudan University | Shanghai | Comprehensive general hospital; cardiovascular, hepatology, and oncology specialty; Phase II; IV trials; top site for liver cancer and hepatocellular carcinoma research given Shanghai's HBV-driven disease burden. |
| 07 | Peking University Cancer Hospital | Beijing | Dedicated oncology research hospital; gastric, colorectal, breast, and lymphoma trials; Phase I; III; Beijing Institute for Cancer Research on campus; partner of major multinational pharma sponsors. |
| 08 | West China Hospital; Sichuan University | Chengdu | One of China's largest hospitals (4,300+ beds); serving Sichuan province (80M+ people); oncology, cardiovascular, neurology trials; critical site for trials seeking access to China's interior population beyond Beijing/Shanghai. |
| 09 | Tongji Hospital; Tongji Medical College, HUST | Wuhan | Central China's premier academic medical center; oncology, cardiovascular, and infectious disease trials; access to Hubei province patient populations; Phase II; IV broad portfolio. |
| 10 | Shanghai Changhai Hospital; Naval Medical University | Shanghai | Leading GI oncology and pancreatology center; Phase I; III in pancreatic cancer, colorectal cancer, and gastroenterology; strong industry-sponsored trial portfolio. |
| 11 | Peking University First Hospital | Beijing | Cardiology, nephrology, and urology specialist; Phase II; IV trials; strong in cardiovascular outcome studies and metabolic disease research; major partner for international cardiovascular trial networks. |
| 12 | Sun Yat-sen Memorial Hospital | Guangzhou | Breast cancer national center; gynecological oncology and hematology; Phase I; III; Greater Bay Area research cluster access; Guangdong province patient population (130M+). |
| 13 | Shanghai Pulmonary Hospital; Tongji University | Shanghai | China's leading respiratory oncology center; lung cancer Phase I; III specialist; thoracic surgery and respiratory disease trials; major partner for global lung cancer multinational studies. |
| 14 | Renji Hospital; Shanghai Jiao Tong University | Shanghai | Rheumatology, gastroenterology, and oncology focus; Phase II; IV; autoimmune disease and IBD trial specialist; Shanghai Zhangjiang biotech cluster access. |
| 15 | The First Affiliated Hospital; Zhejiang University (FAHZU) | Hangzhou | Zhejiang province anchor site; oncology, hepatology, and infectious disease trials; proximity to Hangzhou's tech ecosystem (Alibaba, NetEase health data partnerships); Phase II; IV broad portfolio. |
China's most prestigious academic hospital; affiliated with Chinese Academy of Medical Sciences; broad Phase I; IV portfolio; strong in oncology, rare diseases, and cardiovascular trials; highest research output of any Chinese hospital.
China's national cancer center; leading oncology research institution; Phase I; III across all major tumor types; partner of NCI, IARC, and major multinational sponsors; lung, gastric, esophageal, and cervical cancer specialty.
China's largest cancer specialty hospital; 4,000+ beds; Phase I; IV oncology; breast, GI, thoracic, and hematologic malignancy focus; advanced translational research; international sponsor partnerships with Roche, AZ, BMS.
Premier Shanghai general academic hospital; hematology pioneer (APL treatment developed here); oncology, hematology, endocrinology trials; Phase I unit; major multinational CRO partner site.
South China's leading cancer center; global authority on nasopharyngeal carcinoma; Phase I; III across all major tumor types; strong international research partnerships; access to Southern Chinese and Southeast Asian population genetics.
Comprehensive general hospital; cardiovascular, hepatology, and oncology specialty; Phase II; IV trials; top site for liver cancer and hepatocellular carcinoma research given Shanghai's HBV-driven disease burden.
Dedicated oncology research hospital; gastric, colorectal, breast, and lymphoma trials; Phase I; III; Beijing Institute for Cancer Research on campus; partner of major multinational pharma sponsors.
One of China's largest hospitals (4,300+ beds); serving Sichuan province (80M+ people); oncology, cardiovascular, neurology trials; critical site for trials seeking access to China's interior population beyond Beijing/Shanghai.
Central China's premier academic medical center; oncology, cardiovascular, and infectious disease trials; access to Hubei province patient populations; Phase II; IV broad portfolio.
Leading GI oncology and pancreatology center; Phase I; III in pancreatic cancer, colorectal cancer, and gastroenterology; strong industry-sponsored trial portfolio.
Cardiology, nephrology, and urology specialist; Phase II; IV trials; strong in cardiovascular outcome studies and metabolic disease research; major partner for international cardiovascular trial networks.
Breast cancer national center; gynecological oncology and hematology; Phase I; III; Greater Bay Area research cluster access; Guangdong province patient population (130M+).
China's leading respiratory oncology center; lung cancer Phase I; III specialist; thoracic surgery and respiratory disease trials; major partner for global lung cancer multinational studies.
Rheumatology, gastroenterology, and oncology focus; Phase II; IV; autoimmune disease and IBD trial specialist; Shanghai Zhangjiang biotech cluster access.
Zhejiang province anchor site; oncology, hepatology, and infectious disease trials; proximity to Hangzhou's tech ecosystem (Alibaba, NetEase health data partnerships); Phase II; IV broad portfolio.
These are the primary regulatory, academic, and industry bodies shaping China's clinical research ecosystem.
Primary drug regulator; 60-day IND no-objection window; ICH member since 2017; priority review, breakthrough therapy, and conditional approval pathways; record 46 Class 1 innovative drug approvals in 2024.
NMPA's technical review arm; publishes annual clinical trial progress reports; issues guidance on trial design, pharmacology, and manufacturing; driving alignment with international GCP standards.
Oversees China's healthcare system; hospital accreditation and clinical site certification; manages national reimbursement policies through the National Reimbursement Drug List (NRDL).
China's highest medical research body; operates Peking Union Medical College Hospital and the National Cancer Center; coordinates national clinical research strategy; partner of major international health organizations.
China's largest domestic biotech; global Phase I; III oncology trials; tislelizumab (PD-1) approved across multiple indications; first Chinese biotech to have drugs approved in US, EU, and China simultaneously.
Shanghai-based biotech; licensing and co-development partnerships bridging global and China trials; oncology, infectious disease, and neurology; major vehicle for global sponsors entering China trials.
China's largest CRO/CDMO; full drug development services from discovery through clinical; global operations; major Phase I; IV trial management; regulatory affairs and data management.
Global CRO with major China operations; largest site network; data analytics and real-world evidence; full Phase I; IV management; leading international sponsor gateway into Chinese trial sites.
Global CRO with China operations; oncology, CNS, and cardiovascular specialty; regulatory submissions to NMPA; central laboratory services.
China has undergone the most dramatic transformation in global clinical research of any country in the past decade; from a regulatory backwater to the world's second-most-used trial site, with 13% of global site usage, 4,900 trials registered in 2024, and a domestic biotech sector now producing globally first-in-class drugs. For any multinational program in oncology; particularly gastric, lung, liver, or nasopharyngeal cancer; China's patient scale remains strategically difficult to replicate. The regulatory environment has matured dramatically: 60-day IND review, ICH alignment, and priority pathways now make China one of the more efficient major markets globally. The strategic question for sponsors is no longer whether to include China; it's how to do it most effectively.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.